CN106659736A - 阿尔茨海默病(ad)的治疗和预防 - Google Patents

阿尔茨海默病(ad)的治疗和预防 Download PDF

Info

Publication number
CN106659736A
CN106659736A CN201580029850.7A CN201580029850A CN106659736A CN 106659736 A CN106659736 A CN 106659736A CN 201580029850 A CN201580029850 A CN 201580029850A CN 106659736 A CN106659736 A CN 106659736A
Authority
CN
China
Prior art keywords
aluminum
aluminum salt
oxyhydroxide
patients
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580029850.7A
Other languages
English (en)
Chinese (zh)
Inventor
M.曼德勒
A.施尼伯格
W.佐纳
A.冯博宁
F.马特纳
W.施密特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affiris AG
Original Assignee
Affiris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris AG filed Critical Affiris AG
Publication of CN106659736A publication Critical patent/CN106659736A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
CN201580029850.7A 2014-04-29 2015-04-29 阿尔茨海默病(ad)的治疗和预防 Pending CN106659736A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14166388 2014-04-29
EP14166355.9 2014-04-29
EP14166388.0 2014-04-29
EP14166355 2014-04-29
PCT/EP2015/059341 WO2015165968A1 (en) 2014-04-29 2015-04-29 Treatment and prevention of alzheimer's disease (ad)

Publications (1)

Publication Number Publication Date
CN106659736A true CN106659736A (zh) 2017-05-10

Family

ID=53039897

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580029850.7A Pending CN106659736A (zh) 2014-04-29 2015-04-29 阿尔茨海默病(ad)的治疗和预防

Country Status (12)

Country Link
US (3) US11065273B2 (https=)
EP (2) EP4209222A1 (https=)
JP (1) JP2017515812A (https=)
KR (1) KR102506460B1 (https=)
CN (1) CN106659736A (https=)
AU (1) AU2015254665A1 (https=)
CA (1) CA2946931A1 (https=)
DK (1) DK3137094T3 (https=)
FI (1) FI3137094T3 (https=)
PL (1) PL3137094T3 (https=)
PT (1) PT3137094T (https=)
WO (1) WO2015165968A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3137094T3 (pl) 2014-04-29 2023-03-13 Advantage Therapeutics, Inc. Leczenie i profilaktyka choroby alzheimera (ad)
EP3137097B1 (en) * 2014-04-29 2023-06-21 ADvantage Therapeutics, Inc. Treatment and prevention of alzheimer's disease (ad)
EP3137093B1 (en) * 2014-04-29 2017-09-13 Affiris AG Treatment and prevention of alzheimer's disease (ad)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1646559A (zh) * 2002-04-19 2005-07-27 多伦多大学懂事局 治疗阿尔茨海默氏病的免疫学方法及组合物
CN102834118A (zh) * 2010-03-29 2012-12-19 诺华有限公司 包含与病毒样颗粒偶联的淀粉样β1-6肽及佐剂的组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016327A1 (en) 1993-01-14 1994-07-21 Pollard Harvey B Methods and compositions for blocking amyloid protein ion channels
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
WO2009105641A2 (en) 2008-02-20 2009-08-27 New York University Preventing and treating amyloid-beta deposition by stimulation of innate immunity
AT506820B1 (de) 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
AT506819B1 (de) 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
EP2145898A1 (en) * 2008-07-15 2010-01-20 CHIESI FARMACEUTICI S.p.A. Anti-amyloid immunogenic compositions, methods and uses
GB201101331D0 (en) 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
EP3137097B1 (en) 2014-04-29 2023-06-21 ADvantage Therapeutics, Inc. Treatment and prevention of alzheimer's disease (ad)
EP3137093B1 (en) 2014-04-29 2017-09-13 Affiris AG Treatment and prevention of alzheimer's disease (ad)
PL3137094T3 (pl) 2014-04-29 2023-03-13 Advantage Therapeutics, Inc. Leczenie i profilaktyka choroby alzheimera (ad)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1646559A (zh) * 2002-04-19 2005-07-27 多伦多大学懂事局 治疗阿尔茨海默氏病的免疫学方法及组合物
CN102834118A (zh) * 2010-03-29 2012-12-19 诺华有限公司 包含与病毒样颗粒偶联的淀粉样β1-6肽及佐剂的组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MICHAEL F. POWELL和MARK J. NEWMAN编辑: "《Vaccine Design—The Subunit and Adjuvant Approach》", 31 December 1995 *

Also Published As

Publication number Publication date
DK3137094T3 (da) 2023-02-27
CA2946931A1 (en) 2015-11-05
FI3137094T3 (fi) 2023-03-20
KR20160145821A (ko) 2016-12-20
WO2015165968A1 (en) 2015-11-05
AU2015254665A1 (en) 2016-11-10
US20170049810A1 (en) 2017-02-23
EP3137094B1 (en) 2022-12-07
PT3137094T (pt) 2023-03-09
JP2017515812A (ja) 2017-06-15
US20220000908A1 (en) 2022-01-06
PL3137094T3 (pl) 2023-03-13
US11065273B2 (en) 2021-07-20
EP3137094A1 (en) 2017-03-08
US20240148782A1 (en) 2024-05-09
US11857568B2 (en) 2024-01-02
EP4209222A1 (en) 2023-07-12
KR102506460B1 (ko) 2023-03-03

Similar Documents

Publication Publication Date Title
US20240148782A1 (en) Treatment and prevention of alzheimer's disease (ad)
US20220062412A1 (en) Treatment of alzheimer's disease (ad) with an aluminum salt
CN106659738B (zh) 阿尔茨海默病(ad)的治疗和预防

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20170510

RJ01 Rejection of invention patent application after publication